



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

April 2, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code - INFLUX

Dear Sir/Ma'am,

Sub: Newspaper advertisement of Form PAS-1, in accordance with Section 27 of the Companies Act, 2013.

Pursuant to Section 27 of the Companies Act, 2013 ("the Act") read with Rule 7 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, and other applicable provisions, if any, we enclose herewith copies of the newspaper advertisement in Form PAS-1.

The advertisement provides intimation regarding the notice of special resolution proposed to be passed through Postal Ballot for variation of the alteration of objects referred to in the prospectus. The same was published today, i.e., Thursday, April 2, 2026, in the following newspapers:

1. Financial Express- English Language Daily
2. Mumbai Lakshadweep – Marathi Language Daily (Electronic Edition)

The same shall also be uploaded on the company's website at www.influxhealthtech.com.

We request you to take the above information on record.

Thanking you,

Yours Faithfully,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

GRINDWELL NORTON LTD.

CIN: L26593MH1950PLC008163

Regd. Office: 5th Level, Leela Business Park, Andheri-Kurla Road, Marol, Andheri (East), Mumbai 400 059Tel: +91 22 4021 2121; Email: sharecmt.gno@saint-gobain.com
Website: www.grindwellnorton.co.in**Notice to Shareholders****Second 100-Day "Saksham Niveshak" Campaign & Special Window for Transfer and Dematerialisation of Physical Shares****Second 100-Day "Saksham Niveshak" Campaign - IEPFA**

The Investor Education and Protection Fund Authority ("IEPFA"), Ministry of Corporate Affairs ("MCA") through its intimation dated March 27, 2026, has requested companies to undertake Second 100 days "Saksham Niveshak" Campaign, to reach out to shareholders who have unpaid or unclaimed dividends.

The objective of this initiative is to encourage shareholders to update their KYC details, bank mandates and contact information to facilitate direct payment of the unpaid and unclaimed dividends/shares if any to the rightful shareholder and prevent its transfer to the IEPFA.

Campaign period: April 1, 2026 - July 9, 2026

Shares in physical form:	Shares in demat form:
<ul style="list-style-type: none"> Request letter; Original unclaimed warrant(s), if applicable; Original cancelled cheque; Duly filled KYC forms (ISR-1, ISR-2, SH-13/ISR-3). 	<ul style="list-style-type: none"> Request letter; Self-attested Client Master List (CML), not older than 2 months; Original cancelled cheque.

Special Window for Transfer & Dematerialisation of Physical Shares- SEBI


Pursuant to SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026, a Special Window has been opened for a period of one year for transfer and dematerialisation of physical securities that were sold or purchased prior to April 1, 2019.

This Special Window also covers transfer requests that were earlier submitted but were rejected, returned or not processed due to deficiency in documents, procedural requirements, or any other reason.

Special Window period: February 5, 2026 - February 4, 2027

Documents required:	For Direct credit of securities:
<ul style="list-style-type: none"> Original physical share certificate(s); Transfer deed executed prior to April 1, 2019; Proof of purchase/payment, if available; Form SH-4 with transferee details and appropriate stamp duty; Duly filled forms ISR-1, ISR-2, SH-13/ISR-3; KYC documents of Transferee & Transferor (if available); Undertaking cum Indemnity; 	<ul style="list-style-type: none"> Client Master List (CML) of the transferee, not older than 2 months, duly attested by the Depository Participant ("DP"). Form ISR-4; Demat Conversion Request Form (NSDL)/Demat Request Form (CDSL), provided by the DP signed by the Beneficiary owner.

For any assistance, please contact Company's RTA: **MUFG Intime India Private Limited**
C-101, Embassy 247, LBS Marg, Vikhroli (West), Mumbai 400 083
Tel: +91 81081 16767
Website: in.mpms.mufg.com
Email: investor.helpdesk@in.mpms.mufg.com

Place: Mumbai
Date: April 1, 2026For Grindwell Norton Limited
Sd/-
Girish T. Shajani
Company Secretary

Influx Healthtech Limited
CIN: U24299MH2020PLC346825
Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai: 400067
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra
Phone: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / influxhealthcare1@gmail.com
Website: influxhealthtech.com

Form PAS - 1

[Pursuant to section 27(1) and rule 7(2) of Companies (Prospectus and Allotment of Securities) Rules, 2014]
Advertisement giving details of notice of special resolution for varying the terms of any contract referred to in the prospectus or altering the objects for which the prospectus was issued.

Corporate Identification Number (CIN): L24299MH2020PLC346825
Name of the company: Influx Healthtech Limited
Registered office address: 109, Ghanshyam Enclave Premises, Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai, Maharashtra, India, 400067.

PUBLIC NOTICE

Notice is hereby given that by a resolution dated March 31, 2026, the Board has proposed to alter the object(s) for which the prospectus dated June 23, 2025 issued in connection with issue of 50,00,400 equity shares at an issue price of ₹ 96/- per equity shares (including a share premium of ₹86 per equity share) (offer price) aggregating to ₹ 4,800.38 Lakhs ("fresh issue").

In pursuance of the said resolution, further notice is given that for approving the said proposition, a special resolution is to be passed by postal ballot.

The details regarding such variation/alteration are as follows:-

1. Particulars of the terms of the contract to be varied (or objects to be altered):

The utilisation of the Net Proceeds of the Offer was proposed to be deployed in the following manner, as set forth under the schedule of deployment as disclosed in the Prospectus, as on March 31, 2026.

Division	As per Prospectus	Utilised till 31.03.2026	Remaining as of today	Reallocated	Required
Nutraceutical Division (Plot No. 59)					
Land	139.00	139.00	0.00	0.00	0.00
Building & Civil Works)	787.06	537.67	249.39	0.00	1,796.37
Plant & Machineries	1,323.05	423.83	899.22	393.36	0.00
Total (A)	2,249.11	1,100.50	1,148.61	393.36	1,796.37
Veterinary Food Division (Plot No. 28)					
Land	59.00	59.00	0.00	0.00	0.00
Building & Civil Works	679.23	0.00	679.23	429.23	0.00
Plant & Machineries	410.35	79.00	331.35	120.12	0.00
Total (B)	1,148.58	138.00	1,010.58	549.35	0.00
Purchase of Machineries					
Machine Purchase	275.65	74.96	200.69	66.60	0.00
Total @	275.65	74.96	200.69	66.60	0.00
TOTAL (A+B+C)	3,673.34	1,313.47	2,359.87	1,009.31	1,796.37

The additional amount of ₹1,009.31 Lakhs (₹1,796.37 Lakhs - ₹787.06 Lakhs) required for construction of Plot No. 59 be met by:

- Reallocation of ₹429.23 Lakhs from the amount earmarked for construction of Plot No. 28; and
- Total Reallocation of ₹580.08 Lakhs from the amount earmarked for:
 - Purchase of Machineries of Nutraceutical Division amounting to ₹393.36 Lakhs;
 - Purchase of Machineries of Veterinary Food Division amounting to ₹120.12 Lakhs; and
 - Purchase of Machinery amounting to ₹66.60 Lakhs.

2. Particulars of the proposed variation/alteration:

The Company has revised its project costs, with construction of Plot No. 59 now estimated at ₹1,796.37 Lakhs against ₹787.06 Lakhs in the Prospectus, due to revised specifications, higher infrastructure needs, and cost escalations. In contrast, Plot No. 28's requirement has been optimised to ₹250.00 Lakhs, creating a surplus of ₹429.23 Lakhs. Machinery procurement has also been rationalised, yielding a surplus of ₹580.08 Lakhs from allocations to the Nutraceutical Division, Veterinary Food Division, and other machinery. The Company will retain the original construction plan but will engage additional vendors for allied works such as wiring, fabrication, and finishing, ensuring competitive pricing, timely completion, and quality standards, without altering the fundamental nature of the project.

3. Reasons/justification for the variation:

The variation is proposed pursuant to a reassessment of project requirements and updated cost estimates. The cost of construction at Plot No. 59 has increased due to design revisions, regulatory compliance and escalation in input costs, while requirements at Plot No. 28 and machinery procurement have been optimised, resulting in surplus funds. Accordingly, reallocation is considered prudent for efficient utilisation of IPO proceeds and timely project completion without additional borrowings.

4. Effect of the proposed variation/alteration on the financial position of the company:

The proposed variation will not have any adverse impact on the financial position of the Company as it involves reallocation of existing IPO proceeds without any additional borrowing or finance cost. The reallocation is expected to improve capital efficiency, support timely completion of the project and enhance operational capacity, thereby strengthening long-term financial performance.

5. Major Risk factors pertaining to the new Objects:

The proposed variation may involve risks such as potential increase in construction costs, delays due to regulatory approvals or supply chain disruptions, temporary deferment of machinery impacting scalability, and market demand fluctuations affecting returns; however, the Board considers these risks manageable and the reallocation to be in the best interest of the Company.

6. Names of Directors who voted against the proposed variation/alteration:

None of the Directors has voted against the proposed variation/alteration.

Any interested person may obtain the copy of the special resolution along with the explanatory statement free of charge at the registered office of the company at 109, Ghanshyam Enclave Premises, Co-op Soc Plot No. 856, Laljipada, Kandivali West, Mumbai, Maharashtra, India, 400067 or visit the website of the Company viz. www.influxhealthtech.com for a copy of the same.

For Influx Healthtech Limited
Sd/-
Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

Date: 02.04.2026
Place : Mumbai

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. **NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.** INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE") IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT

Please Scan this QR Code to view the Draft Prospectus

YOGIRAJ POWERTECH LIMITED

(Formerly known as Yogiraj Powertech Private Limited)

Our Company was originally incorporated as 'Yogiraj Powertech Private Limited', as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 29, 2010, issued by the Assistant Registrar of Companies, Maharashtra, Mumbai. Subsequently, our Company was converted to a public limited company and the name of our Company changed to 'Yogiraj Powertech Limited' and a fresh certificate of incorporation dated August 19, 2025 was issued by the Registrar of Companies, Central Processing Centre. For further details of change in name and registered office of our company, please refer to section titled "Our History and Corporate Structure" beginning on page no 158 of the Draft Prospectus.

Registered & Corporate Office: Groma House, Office No. B-2/8/9/10, Plot No. 14C, Sec-19, Vashi, Navi Mumbai, Maharashtra, India, 400705**Contact Person:** Mr. Vikash Jain, Company Secretary & Compliance Officer; **Tel No:** 022 2780 1213,**E-Mail ID:** cs@yogirajpowertech.com, **Website:** www.yogirajpowertech.com; **CIN:** U31400MH2010PLC201398**OUR PROMOTERS: (I) RAVINDRA GANESH NENE; (II) ROHAN RAVINDRA NENE; (III) YOGESH GANESH DESHMUKH; (IV) PRASANNA VINAYAK DATE; AND (V) MADHURA ROHAN NENE**

INITIAL PUBLIC OFFER OF UPTO 65,10,400 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF YOGIRAJ POWERTECH LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹75/- PER EQUITY SHARE, INCLUDING A SHARE PREMIUM OF ₹65/- PER EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING TO ₹ 4,882.80 LAKHS ("THE ISSUE"), OF WHICH 3,34,400 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹75/- PER EQUITY SHARE, AGGREGATING TO ₹250.80 LAKHS WILL BE RESERVED FOR SUBSCRIPTIONS BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 61,76,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹75/- PER EQUITY SHARE, AGGREGATING TO ₹ 4,632.00 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 29.50% AND 27.98% RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF THE COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹10/- EACH AND THE ISSUE PRICE IS ₹ 75/- EACH i.e., 7.5 TIMES OF THE FACE VALUE OF THE EQUITY SHARES. THE MINIMUM LOT SIZE IS 1,600 EQUITY SHARES

THIS OFFER IS BEING MADE IN TERMS OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENT) REGULATIONS, 2018 (THE "SEBI ICDR REGULATIONS") READ WITH RULE 19(2)(b)(i) OF SCRR AS AMENDED. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET OFFER TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 253 (3) OF THE SEBI (ICDR) REGULATIONS, 2018. (For further details please see "The Issue" beginning on page no. 59 of the Draft Prospectus.) A copy will be delivered for filing to the Registrar of Companies as required under sub-section 4 of Section 26 of the Companies Act, 2013.

In terms of Regulation 256 of SEBI ICDR Regulations read with the SEBI Circular No. SEBI/HO/CFD/POD-1/P/CIR/2024/0154 dated November 11, 2024, all the potential investors shall participate in the issue only through an Application Supported by Blocked Amount ("ASBA") process providing details about the bank account which will be blocked by the Self Certified Syndicate Banks ("SCSBs") for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 08, 2019, Individual Investors applying in public issue may use either Application Supported by Blocked Amount (ASBA) process or UPI payment mechanism by providing UPI ID in the Application Form which is linked from Bank Account of the investor. (For details in this regard, specific attention is invited to "Issue Procedure" beginning on page no. 237 of the Draft Prospectus.)

This public announcement is being made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the Draft Prospectus dated March 31, 2026 with EMERGE Platform of National Stock Exchange of India Limited (NSE EMERGE). Pursuant to Regulation 247(1) of the SEBI ICDR Regulations, the Draft Prospectus filed with NSE EMERGE shall be made public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of NSE EMERGE at www.nseindia.com, on the website of the Company at www.yogirajpowertech.com and on the website of the Lead Manager, i.e. Finshore Management Services Limited at www.finshoregroup.com. Our Company invites members of the public to give their comments on the Draft Prospectus filed with NSE EMERGE, with respect to disclosures made in the Draft Prospectus. The members of the public are requested to send a copy of their comments to NSE and/or to the Company Secretary and Compliance Officer of our Company on email id: cs@yogirajpowertech.com and/or the Lead Manager on email id: investors@finshoregroup.com within 21 days from the aforesaid date of filing of the Draft Prospectus with NSE EMERGE.

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 23 of the Draft Prospectus.

Any decision to invest in the Equity Shares described in the Draft Prospectus may only be taken after the Prospectus has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Prospectus from the Draft Prospectus. The Equity Shares, when offered through the Prospectus, are proposed to be listed on the **EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE")**.

For details of the share capital and capital structure and the names of the Signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" beginning on page 74 of the Draft Prospectus. The liability of members of our Company is limited.

For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" beginning on page 158 of the Draft Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE

FINSHORE MANAGEMENT SERVICES LIMITED
Anandlok Building, Block-A, 2nd Floor, Room No. 207,
227 A.J.C Bose Road, Kolkata-700020, West Bengal, India
Telephone: 033 - 2289 5101 / 4603 2561
Email: info@finshoregroup.com
Contact Person: Mr. S. Ramakrishna lyengar
Website: www.finshoregroup.com
Investor Grievance Email: investors@finshoregroup.com
SEBI Registration No: INM000012185
CIN No: U74900WB2011PLC169377

REGISTRAR TO THE ISSUE

INTEGRATED REGISTRY MANAGEMENT SERVICES (P) LIMITED
No 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram,
Bengaluru-560003
Telephone: 080-23460815/816/817/818
Email: smeipo@integratedindia.in
Contact Person: Mr. S Giridhar
Website: www.integratedregistry.in
Investor Grievance Email: giri@integratedindia.in
SEBI Registration Number: INR000000544
CIN No: U74900TN2015PTC101466

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed in the Draft Prospectus.

For **YOGIRAJ POWERTECH LIMITED**

On behalf of the Board of Directors

Sd/-

Ravindra Ganesh Nene**Managing Director****DIN: 02943608**

Place: Navi Mumbai

Date : April 01, 2026

YOGIRAJ POWERTECH LIMITED is proposing, subject to the receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the Draft Prospectus dated March 31, 2026 with EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). The Draft Prospectus is available on the websites of the NSE EMERGE at www.nseindia.com, the website of the Company at www.yogirajpowertech.com and the website of the Book Running Lead Manager, i.e., Finshore Management Services Limited at www.finshoregroup.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" on page 23 of the Draft Prospectus. Potential investors should not rely on the Draft Prospectus filed with NSE EMERGE for making any investment decision.

This announcement has been prepared for publication in India and not to be released or distributed in the United States. This announcement is not an offer to sell or a solicitation of any offer to buy Equity Shares of our Company in any jurisdiction, including the United States. The Equity Shares have not been, and will not be, registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be issued and sold outside the United States in compliance with Regulation S of the Securities Act and the applicable laws of the jurisdiction where those issues and sales occur. The Equity Shares have not been, and will not be, registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

THE LATEST TRENDS IN BUSINESS

THE LATEST TRENDS IN TRENDS

FINANCIAL EXPRESS
Read to Lead

